Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
24 08 2021
Historique:
received: 13 02 2021
accepted: 21 04 2021
entrez: 24 8 2021
pubmed: 25 8 2021
medline: 14 9 2021
Statut: ppublish

Résumé

In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV- DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients.

Identifiants

pubmed: 34427583
pii: S2473-9529(21)00413-4
doi: 10.1182/bloodadvances.2021004515
pmc: PMC8405194
doi:

Substances chimiques

Ki-1 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3227-3239

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Mod Pathol. 2012 Jul;25(7):968-82
pubmed: 22538516
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Hematol Oncol. 2017 Mar;35(1):87-93
pubmed: 26177728
Lancet. 2014 Apr 26;383(9927):1503-1516
pubmed: 24290661
Ann Oncol. 2015 Mar;26(3):548-55
pubmed: 25475080
Hematol Oncol. 2018 Feb;36(1):93-97
pubmed: 28639256
Br J Haematol. 2020 Apr;189(2):257-268
pubmed: 31958882
Br J Haematol. 1999 Mar;104(4):672-9
pubmed: 10192425
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Leuk Lymphoma. 2019 Jan;60(1):19-28
pubmed: 29966474
Mod Pathol. 2011 Aug;24(8):1046-54
pubmed: 21499229
Clin Microbiol Infect. 2015 Jun;21(6):596-602
pubmed: 25743579
Leuk Lymphoma. 2011 Apr;52(4):613-9
pubmed: 21299462
Blood. 2015 Aug 13;126(7):863-72
pubmed: 25999451
Br J Haematol. 2015 Jan;168(1):63-8
pubmed: 25157895
Blood. 2013 Jul 18;122(3):328-40
pubmed: 23649469
Hum Pathol. 2007 Sep;38(9):1293-304
pubmed: 17707260
Br J Haematol. 2014 Dec;167(5):608-17
pubmed: 25135752
Br J Haematol. 2018 Oct;183(1):68-75
pubmed: 30043391
Clin Cancer Res. 2007 Sep 1;13(17):5124-32
pubmed: 17785567
J Hematol Oncol. 2016 Oct 13;9(1):109
pubmed: 27737703
Am J Surg Pathol. 2003 Jan;27(1):16-26
pubmed: 12502924
Am J Surg Pathol. 2019 Mar;43(3):341-351
pubmed: 30540571
Am J Hematol. 2018 Jul;93(7):953-962
pubmed: 29984868
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Pediatr Dev Pathol. 2018 Jan-Feb;21(1):95-99
pubmed: 29187030
Am J Hematol. 2013 Sep;88(9):774-9
pubmed: 23760676
Pathology. 2020 Jun;52(4):453-459
pubmed: 32305135
Blood. 2012 Jan 19;119(3):673-86
pubmed: 22096243
Leuk Lymphoma. 2010 Jan;51(1):66-72
pubmed: 19860616
Hum Pathol. 2009 May;40(5):653-61
pubmed: 19144386
N Engl J Med. 2003 Oct 2;349(14):1324-32
pubmed: 14523140
Eur J Cancer. 2018 Aug;99:86-96
pubmed: 29935491
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):512-6
pubmed: 21889434
Oncologist. 2011;16(1):87-96
pubmed: 21212426
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Eur Rev Med Pharmacol Sci. 2020 Jan;24(17):8947-8956
pubmed: 32964985
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Blood Adv. 2020 Jun 9;4(11):2523-2535
pubmed: 32516416
J Int Med Res. 2020 Feb;48(2):300060519882233
pubmed: 31642356
Haematologica. 2018 Feb;103(2):297-303
pubmed: 29170255
Oncotarget. 2014 Dec 15;5(23):11813-26
pubmed: 25544772
Case Rep Hematol. 2016;2016:2103612
pubmed: 27803821
APMIS. 2011 Apr;119(4-5):309-16
pubmed: 21492232
Adv Anat Pathol. 2011 Sep;18(5):349-55
pubmed: 21841405
Oncotarget. 2016 Sep 13;7(37):59976-59986
pubmed: 27527850
Hum Pathol. 2015 May;46(5):716-24
pubmed: 25704629
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
ACG Case Rep J. 2017 May 24;4:e68
pubmed: 28584842
Br J Haematol. 1997 Dec;99(3):656-64
pubmed: 9401080
Leukemia. 2019 Jul;33(7):1687-1699
pubmed: 30683910
Am J Hematol. 2011 Aug;86(8):663-7
pubmed: 21761432
Leuk Lymphoma. 2013 Feb;54(2):298-303
pubmed: 22830615
Clin Cancer Res. 2014 May 1;20(9):2338-49
pubmed: 24583797
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Virchows Arch. 2015 Nov;467(5):571-82
pubmed: 26369546
Blood. 2011 May 5;117(18):4726-35
pubmed: 21385849
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265
Ann Diagn Pathol. 2016 Dec;25:7-14
pubmed: 27806850
J Hematol Oncol. 2019 Jun 10;12(1):58
pubmed: 31182108
Hum Pathol. 2010 Mar;41(3):352-7
pubmed: 19913281
Cancer. 2017 Sep 1;123(17):3326-3334
pubmed: 28464214
Am J Hematol. 2016 Nov;91(11):1161-1164
pubmed: 27414752
J Clin Oncol. 2015 Nov 10;33(32):3759-65
pubmed: 26261247
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Jpn J Clin Oncol. 2014 Dec;44(12):1164-71
pubmed: 25320341
Nat Rev Immunol. 2003 Oct;3(10):801-12
pubmed: 14523386
Blood. 2007 Aug 1;110(3):972-8
pubmed: 17400912
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
Ann Hematol. 2007 Jul;86(7):493-8
pubmed: 17347847
Histopathology. 2017 Jul;71(1):89-97
pubmed: 28231401
Sci Rep. 2015 Jul 23;5:12168
pubmed: 26202875
Br J Haematol. 2015 Aug;170(4):539-49
pubmed: 25940575
BMC Hematol. 2016 Nov 24;16:28
pubmed: 27904750

Auteurs

Estelle Bourbon (E)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.

Delphine Maucort-Boulch (D)

Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Service de Biostatistique et Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.
Centre national de la recherche scientifique (CNRS), Unité Mixte de Recherche (UMR) 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France.

Juliette Fontaine (J)

Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Claire Mauduit (C)

Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Pierre Sesques (P)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Violaine Safar (V)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Emmanuelle Ferrant (E)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Camille Golfier (C)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Dana Ghergus (D)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Lionel Karlin (L)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Anne Lazareth (A)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Fadhela Bouafia (F)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.

Gian Matteo Pica (GM)

Service d'Hématologie, Centre hospitalier Métropole Savoie, Chambéry, France.

Frédérique Orsini-Piocelle (F)

Service d'Hématologie, Hôpital Annecy-Genevois, Annecy, France.

Clément Rocher (C)

Service d'Hématologie, Groupement Hospitalier Nord Dauphiné, Bourgoin Jallieu, France.

François-Xavier Gros (FX)

Service d'Hématologie clinique et de Thérapies cellulaires and.

Marie Parrens (M)

Service d'Anatomie et de Pathologie, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France.
INSERM U1053, BaRITOn, Université de Bordeaux, Bordeaux, France.

Arthur Dony (A)

Service d'Hématologie, Hôpital Nord-Ouest, Villefranche-sur-Saône, France.

Cédric Rossi (C)

Service d'Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.
INSERM UMR 1231, Dijon, France.

Hervé Ghesquières (H)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and.

Emmanuel Bachy (E)

Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and.

Alexandra Traverse-Glehen (A)

Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France.
EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and.

Clémentine Sarkozy (C)

Département d'Innovation thérapeutique, Institut Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH